Article Text

Download PDFPDF

662 An international survey of practice patterns in ovarian cancer: what we stand for in 2021
  1. B Guani1,2,
  2. L Drouin3,
  3. T Nikolova4,
  4. P Mathevet1,2,
  5. F Lécuru5,
  6. H Azais6,
  7. S Betrian7,
  8. PA Bolze8,
  9. Y Dabi9,
  10. Y Kerbage10,
  11. C Sanson11,
  12. F Zaccarini11,
  13. F Guyon12,
  14. C Akladios13,
  15. HC Hsu14,
  16. S Bendifallah9,
  17. V Balaya1 and
  18. E Deluche15
  1. 1CHUV, Lausanne, Switzerland
  2. 2University of Lausanne, Lausanne, Switzerland
  3. 3CHU de Limoges, Department of Gynecology, Limoges, France
  4. 4Academic Teaching Hospital of Heidelberg University, Baden-Baden, Germany
  5. 5Curie Institut, Breast, gynecology and reconstructive surgery unit, Paris, France
  6. 6Georges Pompidou European Hospital, Gynecologic and Breast Oncologic Surgery Department, Paris, France
  7. 7IUCT Oncopole, Department of medical oncology, Toulouse, France
  8. 8Lyon Sud Hospital Center, Pierre-Bénite, France
  9. 9Tenon Hospital, Paris, France
  10. 10Jeanne de Flandre Hospital, Lille, France
  11. 11Gustave Roussy, Villejuif, France
  12. 12Institute Bergonié, Bordeaux, France
  13. 13Nouvel Hôpital Civil – Hôpitaux Universitaires de Strasbourg, Strasbourg, France
  14. 14National Taiwan University Hospital Hsin-Chu Branch, Taiwan
  15. 15CHU de Limoges, Department of medical oncology, Limoges, France


Introduction/Background*The aim of this study was to investigate the current surgical and non-surgical therapeutic management of advanced epithelial ovarian cancer (AEOC) cases worldwide, using the data from an internationally launched survey.

Methodology After the validation of a 58-item survey regarding diagnostic and pathological data, as well as surgical and chemotherapeutic strategies of AEOC in France, in the period between April and May 2021, the survey was launched among the members of the following gynecological cancer societies and study groups: IJGC Fellows, SENTICOL 3 study group, ARCAGY-GINECO, AGO, SFOG, SFOG Campus and FRANCOGYN.

Result(s)*A total of 203 physicians completed the survey and majority of them, 171 (84.7%) were from Europe. Gynecological oncologists represented 49.2% of the respondents, surgical oncologists 25.1% and medical oncologists 13.7%. Most of the participants work in centers, managing more than 20 AEOC per year (91.5%).

According to 66.7% of respondents, less than 50% of patients were eligible for primary debulking surgery (PDS). If neoadjuvant chemotherapy (NACT) was used, resectability was assessed after 3 cycles of NACT before interval debulking surgery (IDS) was performed. The most used peritoneal carcinomatosis index was Sugarbaker (69.8%), whereas Fagotti, modified Fagotti and Makar scores were used in 35.4%, 20.1% and 4.9%, respectively.

After the initial staging, the decision between PDS and NADS-IDS was based on the number of the surgical procedures which had to be performed (82.9%), carcinosis index (61.6%), patient’s age (51.2%), global visual assessment (36.0%) and surgeon’s personal estimation (11.0%).

During IDS, LION study’s criteria were always applied according to only 23.1% of the respondents. Hyperthermic intraperitoneal chemotherapy (HIPEC) was used as a first-line treatment from 16.0% of respondents within clinical trials and 14.1% out of clinical trials.

Regardless of the surgical strategy (PDS or NACT-IDS) and the completeness of cytoreduction surgery, Olaparib was prescribed by 74.3% to 81.4% of the respondents and Niraparib by 8.6% to 12.9%. Bevacizumab was prescribed by 42.9% to 68.6% in case of no BRCA mutation.

Conclusion*According to our study, the current management of ovarian cancer is in line with the ESGO guidelines. More participants are necessary for a more precise presentation.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.